By writer to www.businesswire.com
HORSHAM, Pa.–(BUSINESS WIRE)–Palladio Biosciences, Inc. (Palladio), a privately-owned, medical stage biopharmaceutical firm growing medicines for orphan illnesses of the kidney, introduced right this moment the outcomes of a examine that investigated using lixivaptan in a affected person with autosomal dominant polycystic kidney illness (ADPKD) who couldn’t tolerate a special vasopressin V2 receptor antagonist, tolvaptan. The presentation can be made as an ePoster through the American Society of Nephrology’s Kidney Week 2020. The convention is being held as a totally digital assembly, October 22-25.
The presentation will embrace the outcomes of greater than 12 months of protected therapy with lixivaptan on this examine, which was carried out as an expanded entry medical examine beneath an IND. The affected person was experiencing vital high quality of life points attributable to her ADPKD, which had initially improved with tolvaptan therapy. Sadly, she developed clinically-meaningful alanine aminotransferase (ALT) elevations, an indication of liver toxicity, on every of three sequential therapy makes an attempt with tolvaptan. This supplied the idea to provoke lixivaptan therapy as an alternative.
“The affected person has not skilled any elevations of ALT or different chemistry assessments throughout therapy with lixivaptan. These outcomes, plus different medical information we are going to current through the convention, spotlight the liver security profile of lixivaptan in sufferers at excessive threat for growing liver toxicity,” mentioned Dr Neil H Shusterman, Chief Medical Officer of Palladio. “To additional examine this potential, we’re at present enrolling sufferers in a bigger examine (PA-ADPKD-303: The ALERT Study during which ADPKD sufferers who beforehand discontinued tolvaptan due to liver chemistry elevations can be handled with lixivaptan.”
Particulars for the poster summary are listed beneath. The ePoster might be seen on-demand beginning October 22 at 10:00 a.m. EDT. Digital convention options embrace an interactive interface and particular communication instruments accessible by means of Kidney Week registration and login. These instruments embrace a dialogue board for every ePoster presentation for Kidney Week members to have interaction in a Q&A session with presenters. The presentation might be accessed on-line on the convention web site with the related hyperlink.
Use of Lixivaptan in a Affected person with Autosomal Dominant Polycystic Kidney Illness (ADPKD) Who Beforehand Skilled Liver Toxicity with Tolvaptan
Poster Quantity: PO1545
Presentation date/time: Thursday, October 22, 10:00 a.m. EDT
About Palladio Biosciences, Inc.
Palladio Biosciences is a privately-held, medical stage biopharmaceutical firm growing medicines for orphan illnesses of the kidney. Palladio is growing its lead drug, lixivaptan, for autosomal dominant polycystic kidney illness (ADPKD), an orphan kidney illness for which there are restricted therapy choices. Lixivaptan is a potent, selective vasopressin V2 receptor antagonist, a mechanism of motion that has medical proof of idea to sluggish kidney perform decline in adults susceptible to quickly progressing ADPKD. Lixivaptan is for investigational use solely. For extra data, please go to Palladio Biosciences.
Polycystic Kidney Illness (PKD) Key Details and Figures
PKD is an inherited genetic illness that impacts as much as 600,00zero folks in america and tens of millions globally. It’s estimated that roughly 140,00zero folks in america have been identified with ADPKD, the most typical sort of PKD. An individual with ADPKD has a 50 p.c probability of passing the illness on to every of his or her youngsters. The illness is characterised by uncontrolled development of fluid-filled cysts within the kidney, which may every develop to be as giant as a soccer. Signs typically embrace kidney infections and ache. The continued enlargement of cysts and substitute of regular kidney tissue causes irreversible lack of renal perform. Yearly there are roughly 2,500 new PKD sufferers in america who require dialysis or a kidney transplant, making PKD the fourth main reason for kidney failure. There isn’t any remedy for PKD.
— to www.businesswire.com